Ariad Pharmaceuticals Company Profile

Aggregated data from the web about Ariad Pharmaceuticals

Company Name	Ariad Pharmaceuticals
Website	https://www.takedaoncology.com
Snippet	An estimated 235,760 people living in the United States were diagnosed with non-small cell lung cancer (NSCLC) in 2021. 1 A lung cancer diagnosis is life-altering, and while we have made great strides in accurate diagnosis and treatment, there is still work to be done to ensure patients with lung cancer feel supported and armed with the information and resources they need to best …
Fate	Merged with Takeda Pharmaceuticals
Defunct	2017
Founded	1991
Revenue	US$118.8M (FY 2015)[1]
Website	www.ariad.com
Industry	Pharmaceuticals, biotechnology
Products	Ponatinib (FDA approved, trade name Iclusig)Ridaforolimus (FDA approved)Brigatinib (FDA approved)Rimiducid (Under development)AP32788 (Under development)
Traded as	NASDAQ: ARIA
Key people	Harvey Berger,Founder, chairman, and CEO EmeritusAlex Denner,Chairman of the BoardTimothy P. Clackson,President of Research and Development and Chief Scientific Officer Ed Fitzgerald, (Former CFO)Marty Duvall, (Former CCO)
Net income	US$(231.16M) (FY 2015)[1]
Former type	Public
Headquarters	Cambridge, MA, United States
Total assets	US$546.69M (FY 2015)[1]
Operating income	US$(217.27M) (FY 2015)[1]
Number of employees	380 (2016)[2]

Ariad Pharmaceuticals is part of the United States company list

Ariad Pharmaceuticals is part of the Biotechnology company list

Ariad Pharmaceuticals is part of the Pharmaceuticals company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.